Sale!

AB-CHMINACA

140.002,600.00

Compare

Description

AB-CHMINACA

AB-CHMINACA

AB-FUBINACA is an indazole-based synthetic cannabinoid

AB-FUBINACA is an indazole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 .

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.

AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.

This product is intended for research and forensic applications.

Technical Information

Formal NameN-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CAS Number1185887-21-1
Molecular FormulaC20H28N4O2
Formula Weight356.5
Purity≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569}
FormulationA crystalline solid
λmax210, 303 nm
SMILESO=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3
InChI CodeInChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1
InChI KeyKJNZIEGLNLCWTQ-KRWDZBQOSA-N

Additional information

Selecte quantity

10 grams, 25 grams, 50 grams, 100 grams, 250 grams, 500 grams, 1000 grams

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.



Exclusive products

Special category of products
Choose your language »
X